Sermorelin has a regulatory history most compounds on this site don't: it was a real, approved drug for over a decade. What happened after its approval — and specifically why it was withdrawn — is the reason it occupies a stronger legal position today than research-only peptides like BPC-157 or Retatrutide.
What Is Sermorelin?
Sermorelin is a 29-amino-acid analog of human growth hormone-releasing hormone (GHRH), representing the fully bioactive fragment of the native hormone.
Mechanism of Action
Sermorelin binds the GHRH receptor on pituitary somatotroph cells, stimulating them to synthesize and release growth hormone. Its half-life is short — roughly 11–12 minutes after IV or subcutaneous dosing — meaning it stimulates a natural GH pulse rather than sustaining elevated GH the way exogenous HGH does. Studies specifically found no significant change in prolactin, LH, FSH, insulin, cortisol, glucose, glucagon, or thyroid hormone levels alongside the GH increase — a selectivity profile that supported its original approval.
Regulatory History — Why This One Is Different
Sermorelin was FDA-approved in 1997 (brand names Geref and Geref Diagnostic) for growth hormone deficiency, including in children. In 2008, the manufacturer (EMD Serono) voluntarily discontinued the product and requested withdrawal of its approval — not for safety or efficacy reasons, but because of manufacturing difficulties.
This distinction has real legal weight: FDA's own Federal Register determination explicitly states GEREF was not withdrawn from sale for reasons of safety or effectiveness. That specific finding is what allows sermorelin to still be legally compounded today by licensed 503A/503B pharmacies under a valid prescription — a materially stronger legal footing than compounds like BPC-157, which were never approved at all.
That compounding-pharmacy pathway is distinct from unprescribed sermorelin sold online as a research chemical. A licensed pharmacy dispensing under prescription and medical supervision is a different legal channel than an unlicensed vendor selling bulk peptide labeled research-use-only — both trace back to the same molecule, but only one involves a prescriber and regulatory oversight.
Where to Source Sermorelin for Research
For legitimate research applications, purity and accurate dosing are critical. We only list vendors who provide third-party HPLC testing and batch-specific Certificates of Analysis.
View the Sermorelin product page →Frequently Asked Questions
Was sermorelin pulled from the market for safety reasons?
No. FDA's own Federal Register determination states explicitly that GEREF (sermorelin) was not withdrawn for reasons of safety or effectiveness — the manufacturer discontinued it in 2008 over manufacturing difficulties. That finding is part of why it remains legally compoundable today.
Is research-vendor sermorelin the same as a compounding pharmacy's prescription version?
No. A compounding pharmacy dispenses under a valid prescription with medical oversight. Sermorelin sold online as a research chemical is unprescribed and not intended for human use — same molecule, different legal channel.
References
1. "Sermorelin: a review of its use in the diagnosis and treatment of children with idiopathic growth hormone deficiency." PubMed. pubmed.ncbi.nlm.nih.gov
2. Federal Register. "Determination That GEREF (Sermorelin Acetate) Injection... Were Not Withdrawn From Sale for Reasons of Safety or Effectiveness." federalregister.gov
This article contains affiliate links. Aura Protocols may earn a commission if you purchase through these links at no additional cost to you. All compounds are for research use only.